Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
Van Meter
S A
SA
Seaburg
H
H
McLendon
B
B
Doraiswamy
P M
PM
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D062787:Drug Overdose / Q000523:psychology*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000506:poisoning*; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012307:Risk Factors; D013406:Suicide, Attempted / Q000523:psychology*
D014150:Antipsychotic Agents; D007328:Insulin; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine